Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Healthcare Copper
Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to patients in Southern California. CSD’s software platform, Electronic Health Records app (EHR), is focused on supporting clinical staff, is a series of assets and functionalities that enhance the customer experience and provide an end-to-end lab solution. The Company, through its subsidiaries, Medivolve Pharmacy Inc., and Kedy Ying Jao D.O., a medical corporation, operate a distributed network of two retail patient-care locations in California, United States. The Company has served hundreds of thousands of patients across the United States and facilitated more than 1,533,000 clinical tests.


OTCPK:MEDVF - Post by User

Medivolve Inc > More good news...$$$
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Post by GeneralWolfeon Apr 08, 2022 9:48am
218 Views
Post# 34587472

More good news...$$$

More good news...$$$Medivolve webinar : Confirmed 200-300mil revenue for 2022, Q4 2021 had $55 mil recievables, significant collection of recievables has occurred with expectation of a max $1.6 mil deduction for bad recievables. Q1 2022 is 'good' comparative to Q4 2021 $180 per patient at the moment. Average revenue per patient per year $1-$2k. (Cross reference to medivolve database of patients they’d have in theory over $1B in recurring revenue) Closest timeline for Telehealth is 3 months for beta test (maybe) and 6 months for commercial. David Preiner is CEO to develop a telehealth business, not to manage a bunch of testing sites. Management believes the stock is significantly undervalued, but can't do anything (considering a share buyback, not a confirmation). New hire Vincent will be handling PR from now on....$$$$$, get in while its dirt cheap...
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities